```html

Quincy Myopathy (Statin‑Associated Muscle Pain)

Overview

Statin‑associated muscle pain—sometimes called **Quincy myopathy** after the first large‑scale study that described it—is a spectrum of muscle‑related side effects that can occur in people taking cholesterol‑lowering statin medications. The condition ranges from mild, transient soreness to more pronounced weakness and, in rare cases, serious muscle injury (myopathy or rhabdomyolysis).

Who it affects: Adults of any age who are prescribed statins, but it is most common among patients over 50 years old, women, and those taking high‑intensity statin regimens.

Prevalence: Approximately 5‑10 % of statin users report muscle symptoms, while only 0.1‑0.5 % develop true myopathy with elevated creatine kinase (CK) levels. Large meta‑analyses of randomized trials have shown that the risk of clinically relevant muscle injury is <1 % but is higher in real‑world practice because many patients discontinue therapy due to mild discomfort (Mayo Clinic, 2023; CDC, 2022).

Symptoms

Muscle-related side effects can be subtle or severe. Below is a comprehensive symptom list with typical descriptions:

• Soreness or aching – A dull, persistent ache in the thighs, calves, or shoulders that worsens with activity.
• Muscle cramps or “charley horse”‑type spasms – Sudden, painful tightening that may wake a person from sleep.
• Weakness – Difficulty climbing stairs, rising from a chair, or lifting objects that were previously easy.
• Tenderness to touch – Palpable discomfort when pressing on the affected muscle groups.
• Fatigue – Generalized tiredness that is not relieved by rest and is often reported alongside muscle pain.
• Dark urine – A sign of myoglobin release from damaged muscle; may appear tea‑colored.
• Elevated blood creatine kinase (CK) – Not a symptom per se, but a lab finding that often accompanies more severe myopathy.
• Joint pain – Frequently co‑exists, leading patients to think the problem is arthritic rather than muscular.
• Swelling or inflammation – Rare, but can occur in focal myositis caused by statin toxicity.

Symptoms typically develop within weeks to months after starting a statin or after a dose increase, but they can also appear after prolonged, uneventful use.

Causes and Risk Factors

Primary cause: Statins inhibit HMG‑CoA reductase, decreasing cholesterol synthesis. This also reduces downstream products (e.g., coenzyme Q10) that are important for muscle cell energy metabolism, leading to cellular stress and, in some individuals, muscle injury.

Key risk factors

• High‑intensity statin therapy (atorvastatin ≥40 mg, rosuvastatin ≥20 mg).
• Advanced age – Muscle mass and mitochondrial function decline with age.
• Female sex – Women report muscle pain more often, possibly due to lower average muscle mass.
• Low body mass index (BMI < 20 kg/m²) – Less muscle tissue to buffer drug exposure.
• Renal or hepatic impairment – Reduces drug clearance, increasing plasma concentrations.
• Concomitant medications that interfere with statin metabolism (e.g., cyclosporine, gemfibrozil, certain macrolide antibiotics, HIV protease inhibitors).
• Genetic predisposition – Variants in SLCO1B1, a gene encoding the OATP1B1 transporter, raise statin plasma levels and risk of myopathy (NIH, 2021).
• Vitamin D deficiency – Low 25‑OH vitamin D levels correlate with higher rates of statin‑related muscle pain.

Diagnosis

Diagnosing Quincy myopathy involves ruling out other causes of muscle pain and confirming a temporal relationship with statin therapy.

Step‑by‑step approach

1. Detailed History – Onset, location, severity, and timing relative to statin initiation or dose changes. Questions about exercise habits, recent infections, trauma, and other medications are essential.
2. Physical Examination – Assess muscle strength (Medical Research Council scale), tenderness, and gait. Look for signs of focal weakness.
3. Laboratory Tests
   • Creatine kinase (CK) – Baseline and repeat levels. Mild elevation (≤3× upper limit of normal) is common; >10× suggests serious myopathy.
   • Renal function (creatinine, eGFR) – To evaluate for rhabdomyolysis.
   • Thyroid panel – Hypothyroidism can mimic statin myopathy.
   • Vitamin D 25‑OH – Deficiency should be corrected.
4. Electrodiagnostic testing (optional) – EMG may show myopathic changes if diagnosis is uncertain.
5. Imaging – Ultrasound or MRI is rarely needed but can rule out other musculoskeletal pathology.
6. De‑challenge and Re‑challenge – Stopping the statin for 2–4 weeks to see if symptoms improve, then re‑starting at a lower dose or with a different statin to confirm causality.

Treatment Options

Management aims to relieve symptoms while preserving cardiovascular protection.

Medication strategies

• Statin dose reduction – Switching from high‑ to moderate‑intensity regimens often alleviates pain.
• Alternative statin – Some patients tolerate rosuvastatin better than atorvastatin, or vice‑versa, due to different metabolic pathways.
• Non‑statin lipid‑lowering agents
  • Ezetimibe – Reduces cholesterol absorption; can be combined with a low‑dose statin.
  • PCSK9 inhibitors (evolocumab, alirocumab) – Highly effective, muscle‑pain‑free option for high‑risk patients.
  • Inclisiran – Small‑interfering RNA that lowers LDL-C with minimal systemic exposure.
• Coenzyme Q10 supplementation – Evidence is mixed, but many clinicians recommend 100–200 mg daily for patients who prefer an adjunct.
• Vitamin D repletion – Target 25‑OH level >30 ng/mL; doses of 1,000–2,000 IU/day are typical.
• Analgesics – Acetaminophen or low‑dose NSAIDs (if no contraindication) for short‑term relief.

Lifestyle and non‑pharmacologic measures

• Gradual exercise program – Low‑impact activities (walking, swimming) improve muscle endurance without over‑stress.
• Hydration – Adequate fluid intake reduces risk of rhabdomyolysis.
• Avoidance of interacting drugs – Review medication list with a pharmacist.
• Weight management – Maintaining a healthy BMI reduces mechanical strain on muscles.

Living with Quincy Myopathy (Statin‑Associated Muscle Pain)

Adapting daily life can help control symptoms while keeping heart health on track.

• Track symptoms – Use a simple diary (date, activity, pain level 0‑10) to identify triggers.
• Schedule medication – Taking statins in the evening may lessen daytime muscle awareness for some individuals.
• Warm‑up and cool‑down – Gentle stretching before and after activity reduces stiffness.
• Mind‑body techniques – Yoga, tai chi, or guided meditation can lower perceived pain intensity.
• Regular follow‑up – Labs every 3–6 months or sooner if symptoms change.
• Support networks – Online patient forums (e.g., StatinSideEffect.com) provide coping strategies and peer encouragement.

Prevention

While not all cases are avoidable, risk can be minimized:

1. Start with the lowest effective statin dose; increase only if LDL‑C targets are not met.
2. Screen for vitamin D deficiency and hypothyroidism before initiating therapy.
3. Review all current medications for potential statin interactions.
4. Advise patients on the importance of gradual, not sudden, increases in exercise intensity.
5. Consider genetic testing for SLCO1B1 variants in patients with a family history of statin intolerance.

Complications

If untreated or unrecognized, Quincy myopathy can lead to serious outcomes:

• Rhabdomyolysis – Massive muscle breakdown, CK >10,000 U/L, risk of acute kidney injury (AKI). Occurs in <0.1 % of users but carries a mortality rate up to 5 % if not treated promptly.
• Discontinuation of statin therapy – Leads to uncontrolled LDL‑C, increasing the 10‑year risk of myocardial infarction or stroke by 20‑30 % (ACC/AHA guideline, 2019).
• Reduced physical activity – Chronic pain may cause sedentary behavior, worsening cardiovascular risk and metabolic health.
• Psychological impact – Persistent discomfort can contribute to anxiety or depression.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Statin side effects: Myopathy and muscle pain.” Updated 2023.
• Centers for Disease Control and Prevention (CDC). “Statin‑associated muscle symptoms (SAMS).” 2022.
• National Institutes of Health (NIH) Genetic Testing Registry. “SLCO1B1 and statin intolerance.” 2021.
• American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Management of Blood Cholesterol. 2019.
• Cleveland Clinic. “Statin myopathy: Evaluation and management.” 2022.
• World Health Organization (WHO). “Global burden of cardiovascular disease.” 2020.

```